250 related articles for article (PubMed ID: 27063550)
1. Regulation of food intake and the development of anti-obesity drugs.
Chen Y
Drug Discov Ther; 2016; 10(2):62-73. PubMed ID: 27063550
[TBL] [Abstract][Full Text] [Related]
2. New and emerging drug molecules against obesity.
George M; Rajaram M; Shanmugam E
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
[TBL] [Abstract][Full Text] [Related]
3. [The pharmacotherapy of obesity].
Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G
Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ; Lee SY
Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic therapies for obesity.
Kaplan LM
Gastroenterol Clin North Am; 2010 Mar; 39(1):69-79. PubMed ID: 20202580
[TBL] [Abstract][Full Text] [Related]
7. Efficacy comparison of medications approved for chronic weight management.
Kumar RB; Aronne LJ
Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S4-7. PubMed ID: 25900871
[TBL] [Abstract][Full Text] [Related]
8. [Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
Ueno H; Nakazato M
Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):753-9. PubMed ID: 24796150
[No Abstract] [Full Text] [Related]
9. Pharmacotherapy of obesity: Available medications and drugs under investigation.
Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
[TBL] [Abstract][Full Text] [Related]
10. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
11. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Shyh G; Cheng-Lai A
Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
[TBL] [Abstract][Full Text] [Related]
12. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic treatment options for obesity: what is old is new again.
Ryan DH; Bray GA
Curr Hypertens Rep; 2013 Jun; 15(3):182-9. PubMed ID: 23625271
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological therapies for obesity.
Kaplan LM
Gastroenterol Clin North Am; 2005 Mar; 34(1):91-104. PubMed ID: 15823441
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for obesity: What you need to know.
Bersoux S; Byun TH; Chaliki SS; Poole KG
Cleve Clin J Med; 2017 Dec; 84(12):951-958. PubMed ID: 29244650
[TBL] [Abstract][Full Text] [Related]
16. Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
Halpern B; Faria AM; Halpern A
Expert Rev Clin Pharmacol; 2013 May; 6(3):235-41. PubMed ID: 23656337
[TBL] [Abstract][Full Text] [Related]
17. Comparison table: some FDA-approved drugs for weight management.
Med Lett Drugs Ther; 2018 Jun; 60(1548):e98-e100. PubMed ID: 29913464
[No Abstract] [Full Text] [Related]
18. Drug treatment of obesity.
Bray GA
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Apr; 13(1):131-48. PubMed ID: 10932681
[TBL] [Abstract][Full Text] [Related]
19. Obesity: Current Treatment and Future Horizons.
Omran Z
Mini Rev Med Chem; 2017; 17(1):51-61. PubMed ID: 27320641
[TBL] [Abstract][Full Text] [Related]
20. Person-centered choice of anti-obesity pharmacotherapy.
Kalra S; Arora S; Kapoor N
J Pak Med Assoc; 2022 Jul; 72(7):1449-1450. PubMed ID: 36156581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
